Peter Hanson Email & Phone Number

At VetrixBio, we are developing next generation medicines for two of the most common and disabling diseases in dogs: cancer and osteoarthritis (OA). More than 4.2 million dogs annually are diagnosed with cancer and the standard of care (SOC) today relies on dated chemotherapy and radiation. Efficacy is often limited, and serious adverse events are common. We intend to change that.OA affects as many as 40% of young dogs and 80% of dogs aged 8 years and older, with the SOC limited to pain relief rather than treating the underlying disease. We are adding disease modification to pain management.

Amsterdam, Nl

Anterra identifies next-generation science for major therapeutic targets in animal health on which to launch the next portfolio company.

With more than 28 years experience in veterinary pharma and human biotech, I provide consulting on biotechnology research, clinical development, manufacturing and business operations, including IPO readiness.

Cambridge, Ma, Us

eGenesis is advancing the field of transplantation to make available safe and reliable xeno organs, tissues, and cells to patients in need. This is done through gene editing technology such as CRISPR to directly address the key virology and immunology hurdles that have impeded xenotransplantation to date.

Boston, Ma, Us

Centrexion is pioneering new treatments to relieve the suffering associated with chronic pain by developing non-opioid and non-addictive therapies.

Abbott Park, Illinois, Us

Our vision was to be recognized for consistently setting new standards in healthcare solutions that enrich the human/pet bond. Our programs included the areas of pain, oncology and medical devices.

Ingelheim Am Rhein, Rhineland-Palatinate, De

Responsible for the team of project leaders and project managers for the company's portfolio of veterinary pharmaceutical and vaccine development projects. Scope was global.

Ingelheim Am Rhein, Rhineland-Palatinate, De

Responsible for discovery screening, chemical development, formulation development, analytical development, and DMPK for small molecule pharmaceutical projects.

Ingelheim Am Rhein, Rhineland-Palatinate, De

Led development of PREVICOX and EQUIOXX to global approvals and a team of other project leaders.

Madison, Wi, Us

Residency in large animal surgery. Graduate work in bone biomechanics and bone transplantation/healing, leading to MS and PhD. Lectured in large animal anatomy.

Associate veterinarian with a split 70% equine and 30% small animal.

Ms / Phd / Residency, Veterinary Science And Large Animal Surgery

Dvm, Ba Summa Cum Laude - Biology